
The CAR T-cell therapy JCAR015 received breakthrough therapy designation as a treatment for patients with relapsed or refractory B-cell ALL.

The CAR T-cell therapy JCAR015 received breakthrough therapy designation as a treatment for patients with relapsed or refractory B-cell ALL.

When caring for someone who has undergone brain surgery, practice patience and ask for support.

Experts offer suggestions on post-surgery care after brain cancer.

Gaining access to that top-notch doctor or medical center can present a larger hurdle for someone with an uncommon malignancy, but it is possible with a few tips.

A Q&A with Maureen Rigney, director of community and support services for the Lung Cancer Alliance.

Patients who undergo surgery for brain cancer may need to be patient during recovery.

Finding new treatment options for my metastatic lung cancer

A competition and mural project allow those affected by cancer to express themselves through art.

Given the mixed messages involved, it's not surprising that women with ductal carcinoma in situ can become anxious and sometimes unduly alarmed by the diagnosis.

Investigational vaccine appears to help progression-free survival and overall survival in patients with a type of glioblastoma.

Immunotherapy is coming of age not only in general oncology, but also in neuro-oncology.

As a nonsmoker, lung cancer was never on my radar, especially not metastatic lung cancer.

The FDA approves Avastin in combination with chemotherapy for patients with platinum-resistant recurrent ovarian cancer, based on results of the phase 3 AURELIA trial.

Approved and investigational agents have improved outcomes for patients with follicular lymphoma; however a growing understanding of the origins and progression of the disease might offer further insights for future clinical development.

With the agency's proposal to cover lung cancer screening, focus turns to implementation and increasing cures.

As new therapies enter the treatment landscape for metastatic colorectal cancer, oncology nurses become even more critical in educating patients about side effects and the importance of reporting adverse events promptly.

When faced with a cancer diagnosis, it's like being lost in a maze without a map where everyone speaks a language you don't understand and expects questions you don't know to ask.

With advances in screening strategies and targeted therapy for lung cancer, the arrival of immunotherapy looks to be the next big step in helping patients with the disease.

What began as an awareness campaign—men sporting mustaches in November in support of men's health—now has spurred one of the largest investments in improving the quality of life for men with prostate cancer.

To further the goal of every survivor receiving a survivorship care plan, the American Society of Clinical Oncology unveiled a new two-page template, updated from its 2006 original.

Why is November not named an "awareness month?" Because stomach cancer isn't only about awareness.

The FDA approves Cyramza (ramucirumab) in combination with paclitaxel for the treatment of advanced gastric cancer or GEJ adenocarcinoma.

Cancer-free days include ordinary, fun simple moments of joy

A consensus has emerged that palliative care should not be seen as end-of-life care but is best deployed early to help patients and their caregivers manage symptoms throughout the cancer treatment trajectory.

Ask a number of people how they received unsettling news about their cancer and most will remember in striking detail, but a doctor-led program aims to help physicians learn how to break bad news better. Will it help?

The FDA has granted a breakthrough therapy designation to the immunotherapy drug Keytruda (pembrolizumab) for the treatment of patients with non-small cell lung cancer.

In September, The Ohio State University Comprehensive Cancer Center, collaborating with the Department of Emergency Medicine, opened a fully integrated cancer emergency department at the new James Cancer Hospital to care for patients who develop emergencies caused by their cancers.

Preliminary data from a phase 2 trial demonstrates that a combination of the PARP inhibitor veliparib and chemotherapy benefits patients with squamous cell non-small cell lung cancer.

Being a parent affects EVERY decision in my life, even the ones regarding my cancer care.

Recently approved Akynzeo prevents common side effect with a combination approach.